Cell Cycle

Cell cycle is the entire process of cell division from the completion of one division to the end of the next division and is divided into two phases: interphase and division. Life is a continuous process passed from generation to generation and is therefore a process of constant renewal and starting from scratch. Thus, it is a process of constant renewal and starting from scratch. The life of a cell begins with the division of its parent cell and ends with the formation of its daughter cells, or the death of the cell itself. Usually, the formation of daughter cells is considered to mark the end of cell division. The cell cycle is the process from the formation of daughter cells at one cell division to the formation of daughter cells at the next cell division. During this process, the genetic material of the cell is copied and distributed equally to the two daughter cells.

Cat. No.	Product name
BP13409	Palbociclib
BP13409	Palbociclib is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation.
BP13410	Pelitrexol
BP13410	Pelitrexol (AG 2037) is a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor.
BP13411	Rac1 Inhibitor W56 acetate(1095179-01-3 free base)
BP13411	Peptide comprising residues 45-60 of the guanine nucleotide exchange factor (GEF) recognition/activation site of Rac1; selectively inhibits Rac1 interaction with Rac1-specific GEFs TrioN, GEF-H1 and Tiam1.
BP13412	PF-06873600
BP13412	PF-06873600 is a selective and orally bioavailable cyclin-dependent kinase (CDK) inhibitor(CDK2, CDK4 and CDK6 with Ki of 0.09 nM, 0.13 nM and 0.16 nM, respectively), has potential antineoplastic activity.
BP13413	PF07104091
BP13413	PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
BP13414	PF-562271 besylate
BP13414	PF-562271 (besylate) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.
BP13415	PHA-767491
BP13415	PHA-767491 is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.
BP13416	Phleomycin
BP13416	Phleomycin is one of the anticancer glycopeptide antibiotics which cause DNA cleavage. It is similar to Bleomycin which binds and intercalates DNA to damage the integrity of the double helix.
BP13417	Phthalazinone pyrazole
BP13417	Phthalazinone pyrazole is potent, selective, and orally bioavailable inhibitor of Aurora-A kinase. Aurora-A is overexpressed in a variety of tumor types and displays oncogenic activity.
BP13418	PNU112455A hydrochloride
BP13418	PNU 112455A is an ATP site competetive inhibitor of CDK2 and CDK5,binds to the ATP site of CDK2 and CDK5 with Kms of 3.6 and 3.2 μM, respectively.
BP13419	Poloxime
BP13419	Poloxime is a hydrolysis product of poloxin and is a non-ATP-competitive Plk1 inhibitor. It also has moderate Plk1 inhibitory activity.
BP13420	Poloxin
BP13420	Poloxin is a non-ATP competitive Polo-like Kinase 1 inhibitor. It targets the polo-box domain (IC50: appr 4.8 μM).
BP13421	Pritelivir
BP13421	Pritelivir (BAY 57-1293) is a potent helicase-primase inhibitor with active against HSV-1 and HSV-2 (IC50: 20 nM).
BP13422	Procaine hydrochloride
BP13422	Procaine Hydrochloride is the hydrochloride salt form of procaine, a benzoic acid derivative with local anesthetic and antiarrhythmic properties. Procaine binds to and inhibits voltage-gated sodiumchannels, thereby inhibiting the ionic flux required for the initiation and conduction of impulses. In addition, this agent increases electrical excitation threshold, reduces rate of rise of action potential and slows nerve impulse propagation thereby causing loss of sensation.
BP13423	Procaine
BP13423	Procaine is a local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block.
BP13424	Procarbazine hydrochloride
BP13424	Procarbazine Hydrochloride is the hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.
BP13425	Proguanil hydrochloride
BP13425	Proguanil Hydrochloride is a biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.Upon hydrolysis, proguanil is converted to its active cyclic triazine metabolite, cycloguanil, by a cytochrome P450 dependent reaction. Cycloguanil selectively inhibits the bifunctional dihydrofolate reductase-thymidylate synthase of plasmodium parasite, thereby disrupting deoxythymidylate synthesis and ultimately blocking DNA and protein synthesis in the parasite.
BP13426	PROTAC CDK2/9 Degrader-1
BP13426	PROTAC CDK2/9 Degrader-1 is a potent CDK2 and CDK9 dual degrader(DC50 of 62 nM and 33 nM).
BP13427	PROTAC CDK9 Degrader-1
BP13427	PROTAC CDK9 Degrader-1 is a selective CDK9 degrader.
BP13428	Protein kinase inhibitors 1
BP13428	Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.